The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | The efficacy of CAR T-cell therapy in Richter’s transformation
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, discusses a study investigating the efficacy of CAR T-cell therapy in Richter’s transformation. The study revealed relatively short progression-free survival (PFS), and Dr Woyach emphasizes the need for further research to explore the potential role of early intervention with CAR T-cell therapy, possibly as a bridge to transplantation. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Richter’s transformation remains an unmet clinical need in CLL, and many therapies have been tested in this disease with varying success, but usually, unfortunately, when we’ve adapted things to a real-world setting, the efficacy has decreased. In this study, we actually looked at patients with Richter’s transformation treated with CAR T-cells in a multicenter setting. This was based on some preliminary data from our institution at Ohio State as well as a couple of other studies that had suggested that there was some benefit to the use of CAR-T in CLL...
Richter’s transformation remains an unmet clinical need in CLL, and many therapies have been tested in this disease with varying success, but usually, unfortunately, when we’ve adapted things to a real-world setting, the efficacy has decreased. In this study, we actually looked at patients with Richter’s transformation treated with CAR T-cells in a multicenter setting. This was based on some preliminary data from our institution at Ohio State as well as a couple of other studies that had suggested that there was some benefit to the use of CAR-T in CLL. Here we saw actually a relatively short progression free survival overall for patients who received CAR-T therapy. Importantly, though, many of these patients had received multiple lines of therapy prior to getting to CAR-T. And I think that it still remains an open question if we were to treat patients with Richter’s transformation with CAR-T early or potentially instead of using it as a destination therapy, use it as a bridge for transplant. I think there still is potentially a role for this therapy, but it needs to be further studied.
Read more...
Disclosures
Consultancy: Newave, Loxo, Beigene, AstraZeneca, Abbvie, Janssen, Pharmacyclics; Research Funding: Schrodinger, Morphosys, Karyopharm, Janssen, Pharmacyclics.
